ArticleNature medicine2026

Obinutuzumab β for aquaporin-4-positive neuromyelitis optica spectrum disorder: a phase 3 randomized controlled trial.

Lei Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.